Relative Bioavailability of Ferric Pyrophosphate From an Apple Juice Drink

NCT ID: NCT00474682

Last Updated: 2008-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to find out how well iron is absorbed when a newly developed form of ferric pyrophosphate is added to a commercial apple juice drink.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Micronized dispersible ferric pyrophosphate (MDFP) is an iron compound that has been reported to be highly bioavailable and likely to cause few sensory problems when added to food. It is therefore a potentially effective iron additive for the food industry and is particularly formulated for adding to liquids. A randomized cross-over trial will be undertaken to compare the absorption of iron added to a commercial apple juice drink as MDFP with iron added as ferrous sulphate. The null hypothesis is that absorption of iron added as MDFP is not different to absorption from iron added as ferrous sulphate.

The study population will consist of 16 women (age 18-65) with iron stores at the lower end of the normal range. This group will efficiently absorb bioavailable iron and will be sensitive to differences in bioavailability between different forms of iron. Test drinks containing added iron, labelled with stable isotopes of iron (Fe-57 or Fe-58), will be consumed on two consecutive days. Iron absorption from the drinks will be determined using the erythrocyte incorporation technique. A baseline blood sample will be taken prior to consuming the test drinks and then a second blood sample will be taken 14 days after the last test drink. Iron absorption will be calculated from the isotopic enrichment of the final blood sample, assuming that 80% of absorbed iron is incorporated into red blood cells. The order in which the volunteers will be given the MDFP or ferrous sulphate will be randomised.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Iron Deficiency

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

ferric pyrophosphate, iron bioavailability, fortification,

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Micronized dispersible ferric pyrophosphate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women
* Age \>18 and \<65
* BMI \>18.5 and \<35
* Serum ferritin value of =12μg/L and =50μg/L

Exclusion Criteria

* Men
* Age \< 18 or \>65
* BMI \<18.5 or \>35
* Serum ferritin value of \<12μg/L or \>50μg/L
* Volunteers will be excluded if they are found to have depressed or elevated blood pressure measurements (\<90/50 or\<95/50 if symptomatic or \>160/100)
* Diagnosed with a long-term illness requiring active treatment, e.g. diabetes, cancer, cardiovascular disease
* Gastrointestinal disease (excluding hiatus hernia unless symptomatic)
* Regular prescribed medication that may interfere with iron metabolism
* Regular use of antacids and laxatives (at least once a week)
* Women who are pregnant or less than 12 months since giving birth
* Women breast feeding
* Vitamin supplements with or without minerals if taken more than once a week, and unwillingness to discontinue occasional use for the duration of study
* Unwillingness to discontinue use of herbal supplements for the duration of study
* Use of antibiotics within four weeks prior to study start
* Parallel participation in another study which involves dietary interventions or sampling of blood that may increase the volume taken above 500ml in a 4-month period.
* Asthma requiring treatment within the last two years
* Results of clinical screening which indicate, or are judged by the HNU Medical advisor to be indicative of a health problem which could compromise the well-being of the volunteer if they participated or which would affect the study data.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Coca-Cola Company

INDUSTRY

Sponsor Role collaborator

Quadram Institute Bioscience

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Susan J Fairweather-Tait

Role: PRINCIPAL_INVESTIGATOR

University of East Anglia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Food Research

Norwich, Norfolk, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IFR04/2006

Identifier Type: -

Identifier Source: org_study_id